Marc S. Hoffmann, MD, discusses current data for sonrotoclax plus zanubrutinib and upcoming trials for the combination in mantle cell lymphoma.
Back
Assessing a Novel BCL-2 Inhibitor–Based Combination in R/R Mantle Cell Lymphoma
Jacob Soumerai, MD, and colleagues shared updated data for sonrotoclax plus zanubrutinib in relapsed/refractory mantle cell lymphoma.
Assessing a Novel BCL-2 Inhibitor–Based Combination in R/R Mantle Cell Lymphoma
Episodes
All
All
Sonrotoclax plus zanubrutinib yielded deep, durable responses at the recommended phase 2 dose in relapsed/refractory MCL.
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Long-Term Follow-Up Confirms Tivozanib Monotherapy Efficacy in 2L/3L mRCC
4
Colorectal Cancer Isn't the Only Gastrointestinal Cancer Rising in Young Adults
5